{"filing":{"accession_number":"0001559053-26-000021","cik":"0001559053","ticker":"PRTA","company_name":"PROTHENA CORP PUBLIC LTD CO","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"prta-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1559053/000155905326000021/prta-20260806.htm"},"events":[{"id":25814,"run_id":23434,"accession_number":"0001559053-26-000021","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Prothena issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, including net loss of $18.6 million for Q2 and net income of $14.1 million for the first six months of 2026, total revenue of $52.1 million for H1 2026 (primarily from a $50.0 million milestone payment from Novo Nordisk), and updated 2026 financial guidance. The press release is furnished as Exhibit 99.1 and constitutes a standard quarterly earnings disclosure under Item 2.02.","company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26738,"accession_number":"0001559053-26-000021","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Prothena issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, including net loss of $18.6 million for Q2 and net income of $14.1 million for the first six months of 2026, total revenue of $52.1 million for H1 2026 (primarily from a $50.0 million milestone payment from Novo Nordisk), and updated 2026 financial guidance. The press release is furnished as Exhibit 99.1 and constitutes a standard quarterly earnings disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:35:46.434486+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26738,"accession_number":"0001559053-26-000021","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Prothena issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, including net loss of $18.6 million for Q2 and net income of $14.1 million for the first six months of 2026, total revenue of $52.1 million for H1 2026 (primarily from a $50.0 million milestone payment from Novo Nordisk), and updated 2026 financial guidance. The press release is furnished as Exhibit 99.1 and constitutes a standard quarterly earnings disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:35:46.434486+00:00","company_name":"PROTHENA CORP PUBLIC LTD CO","ticker":"PRTA","filing_date":"2026-08-06"}]}